Jeppe Krog RasmussenFounder & Chief Executive Officer (CEO), Member of the Board
Jeppe Krog Rasmussen, Founder and CEO at DanCann Pharma since its formation in 2018. Jeppe has been a part of the whole DanCann Pharma journey since its beginning back in March 2018, where he founded the Company. Jeppe is responsible for the strategic direction and operational execution of all processes relevant to DanCann Pharma.
In addition to DanCann Pharma Jeppe runs his investment company, JKR Investment Group ApS, where he manages his investment portfolio.
John Morell FrellsenInterim. Chief Commercial Officer (CCO)
John Morell Frellsen holds a Master’s Degree in Business Economics and Language from the University of Southern Denmark. In addition, John has completed several educational programmes at INSEAD, France.
John is an experienced executive with a history of working with purchasing, sales and distribution of pharmaceuticals within companies such as Bonorum Partners ApS, Morellco Pharma A/S, AtrimusRX AB, Unimedic Pharma A/B and Orifarm A/S
Mads MøllerChief Financial Officer (CFO)
Mads Møller Kristensen holds a M.Sc. in Business Economics and Auditing. He has been the Chief Financial Officer (CFO) of DanCann Pharma A/S since May 2020, and or more than 8 years he has worked with in all aspects of strategy, finance, management, processes, organizational development and business development.
Among others he has held positions at Viking Life-Saving Equipment A/S, Martinsen Statsautoriseret Revisionspartnerselskab and Arctiko A/S.
Morten MartinsenChief Operating Officer (COO)
Morten Martinsen holds a B.Sc. in Biology and a M.Sc. in Climate Change from the University of Copenhagen. Morten has been the Chief Operating Officer (COO) of DanCann Pharma A/S since 2018. Mortens major point of focus is on state-of-the-art technologies for indoor cultivation of medicinal crops, including Cannabis.
During his years of study, Martinsen specialized in vertical farming technology and energy optimization in the horticultural industry. In addition, Martinsen has been engaged in the pharma industry for serval years through his work at Nomeco A/S under GDP and GMP regulations.